Overview

• Partners attribute the price reduction to process improvements, expanded production capacity, cost‐effective manufacturing and minimal profit margins
• GSK will transfer manufacturing technology to Bharat Biotech and continue supplying the vaccine’s adjuvant until full production handover by 2028
• Bharat Biotech has invested over $200 million in high‐output facilities and product development to support scaling up of GaviS Gavi has received funding commitments for its 2026-2030 phase but contributions have fallen short of the alliance’s projected needs
• Malaria kills more than 500,000 people each year, mainly children under five in sub-Saharan Africa, underscoring the vaccine’s potential to save lives